has a chance to draw level again with Merck & Co's rival cancer immunotherapy Keytruda (pembrolizumab), which was approved for adjuvant treatment of melanoma last December. Securing approvals in ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...

Major pathologic response serves as a key factor in determining subsequent adjuvant ... compared with pembrolizumab monotherapy in patients with high-risk, resected stage III melanoma while ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

This page is about targeted cancer drugs and immunotherapy for melanoma ... pembrolizumab (Keytruda). A nurse gives it to you as a drip into your blood stream (intravenously). It helps reduce the risk ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as ...

The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies.

Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...

A Bristol Myers Squibb immunotherapy currently approved as a first-line treatment for metastatic melanoma has failed a pivotal clinical trial intended to support expanding the therapy’s use to ...

Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475 ... syndrome [TSID11993] Technology appraisal guidance Pembrolizumab with lenvatinib ...

Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy ...

Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS [ID9659] Technology appraisal guidance Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 ...